Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
Alwin Krämer(Heidelberg University), Stefan Kasper(Essen University Hospital), Gunnar Folprecht, Katharina Schütte(Marienhospital Stuttgart), Ralf‐Dieter Hofheinz(University of Mannheim), Karolin Trautmann(Universität Hamburg), Carsten Bokemeyer(Universität Hamburg), Viktor Grünwald(Deutsche Schmerzgesellschaft), Alexander Stein(Universität Hamburg), H. Löffler(University of Mannheim), Claus‐Henning Köhne(Klinikum Oldenburg), Albrecht Kretzschmar(Roche (Switzerland)), Michael Stahl(Kliniken Essen-Mitte), G. Huebner(Westpfalz Klinikum)
Cited by 7
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k